Inventor · disambiguated record
Jie Li
Also filed as: LI JIE · LI JIE J · LI JIE JACK
48 granted patents·49 pending applications·149 citations·filing 1999–2024
97Inventor score
Files withSIEMENS HEALTHCARE DIAGNOSTICS INC9REVOLUTION MEDICINES INC6SCRIPPS RESEARCH INST5UNIV MIAMI5MEDSHINE DISCOVERY INC4
Top patents by PatentIndex Score
97 records- 0193US8147825B2Topical co-enzyme Q10 formulations and methods of useHSIA SUNG LAN·Filed 2005·Granted Apr 3, 2012·23 cites·19 claims
- 0292US8771680B2Topical co-enzyme Q10 formulations and methods of useUNIV MIAMI·Filed 2013·Granted Jul 8, 2014·12 cites·13 claims
- 0392US8586030B2Co-enzyme Q10 formulations and methods of useUNIV MIAMI·Filed 2013·Granted Nov 19, 2013·12 cites·13 claims
- 0492US8293227B2Topical co-enzyme Q10 formulations and methods of useHSIA SUNG LAN·Filed 2012·Granted Oct 23, 2012·16 cites·10 claims
- 0591US8562976B2Co-enzyme Q10 formulations and methods of useHSIA SUNG LAN·Filed 2012·Granted Oct 22, 2013·12 cites·19 claims
- 0689US10786567B2Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicineSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Sep 29, 2020·4 cites·18 claims
- 0788US6869958B2Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitorsWARNER LAMBERT CO·Filed 2003·Granted Mar 22, 2005·21 cites·14 claims
- 0885US11091549B2Single domain antibody and derivative proteins thereof against CTLA4SUZHOU ALPHAMAB CO LTD·Filed 2017·Granted Aug 17, 2021·3 cites·12 claims
- 0985US2024351033A1Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytesSIEMENS HEALTHCARE DIAGNOSTICS INC·Filed 2024·Application pending·0 cites
- 1083US11286248B2Pyrazine-2(1H)-ketone compound acting as FGFR inhibitorZHANGZHOU PIEN TZE HUANG PHARM·Filed 2019·Granted Mar 29, 2022·3 cites·18 claims
- 1182US11459337B2Isothiazolo[5,4-D]pyrimidine compound as IRAK4 inhibitorCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2019·Granted Oct 4, 2022·2 cites·20 claims
- 1281US11434232B2ATR inhibitor and application thereofWUXI BIOCITY BIOPHARMACEUTICS CO LTD·Filed 2019·Granted Sep 6, 2022·2 cites·19 claims
- 1381US9804176B2Assays for vitamin D epimersSIEMENS HEALTHCARE DIAGNOSTICS INC·Filed 2015·Granted Oct 31, 2017·2 cites·12 claims
- 1481US2023149292A1Co-enzyme q10 formulations and methods of useUNIV MIAMI·Filed 2022·Application pending·0 cites
- 1580US12053775B2Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytesSIEMENS HEALTHCARE DIAGNOSTICS INC·Filed 2022·Granted Aug 6, 2024·0 cites·12 claims
- 1680US11613545B2Macrocyclic compound serving as Wee1 inhibitor and applications thereofWUXI BIOCITY BIOPHARMACEUTICS CO LTD·Filed 2018·Granted Mar 28, 2023·2 cites·20 claims
- 1779US11464780B2Pyrazolopyrimidine derivative and use thereofSimcere pharmaceutical co ltd·Filed 2019·Granted Oct 11, 2022·2 cites·19 claims
- 1879US2024208996A1Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereofSIEMENS HEALTHCARE DIAGNOSTICS INC·Filed 2024·Application pending·0 cites
- 1978US6548499B1Substituted quinoxaline derivatives as interleukin-8 receptor antagonistsMILLENNIUM PHARM INC·Filed 1999·Granted Apr 15, 2003·24 cites·20 claims
- 2075US11753619B2Engineered cells and methods of useSCRIPPS RESEARCH INST·Filed 2018·Granted Sep 12, 2023·1 cites·7 claims
- 2175US11739093B2Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2019·Granted Aug 29, 2023·1 cites·18 claims
- 2275US11214577B2Morphinans useful for treating medical disordersHumanwell Pharmaceutical US·Filed 2020·Granted Jan 4, 2022·1 cites·12 claims
- 2373US11021445B2Carboxylic acid derivative as AT2R receptor antagonistSHANDONG DANHONG PHARMACEUTICAL CO LTD·Filed 2019·Granted Jun 1, 2021·1 cites·20 claims
- 2473US8912220B2Compounds and methods of use thereofELDER AMY·Filed 2010·Granted Dec 16, 2014·4 cites·20 claims
- 2573US2021128453A1Co-enzyme q10 formulations and methods of useUNIV MIAMI·Filed 2020·Application pending·0 cites
- 2671US12365688B2Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Jul 22, 2025·0 cites·36 claims
- 2771US11358143B2Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytesSIEMENS HEALTHCARE DIAGNOSTICS INC·Filed 2020·Granted Jun 14, 2022·0 cites·16 claims
- 2870US11912768B2Single domain antibody and derivative proteins thereof against CTLA4SUZHOU ALPHAMAB CO LTD·Filed 2021·Granted Feb 27, 2024·0 cites·9 claims
- 2970US9746484B2Binding partners specific for vitamin D epimers in vitamin D assaysSIEMENS HEALTHCARE DIAGNOSTICS INC·Filed 2015·Granted Aug 29, 2017·1 cites·12 claims
- 3070US2024067636A1Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 3170US2024101577A1Polycyclic compounds as allosteric shp2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 3268US11958863B2Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereofSIEMENS HEALTHCARE DIAGNOSTICS INC·Filed 2019·Granted Apr 16, 2024·0 cites·20 claims
- 3366US11702411B2Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jul 18, 2023·0 cites·6 claims
- 3465US2014255372A1Co-enzyme q10 formulations and methods of useUNIV MIAMI·Filed 2014·Application pending·0 cites
- 3565US2025313633A1Anti-B7H3 antibody and Uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 3665US2023348846A1Engineered cells and methods of useSCRIPPS RESEARCH INST·Filed 2023·Application pending·0 cites
- 3764US2025154279A1Anti-gpc3 and anti-cd137 multispecific antibodies and methods of useBEIGENE LTD·Filed 2024·Application pending·0 cites
- 3863US8119658B2Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitorsLI JUN·Filed 2008·Granted Feb 21, 2012·0 cites·20 claims
- 3963US2024384281A1Methods of improving vitamin d levels in plantsINNES JOHN CENTRE·Filed 2022·Application pending·0 cites
- 4063US2024209106A1Anti-cd137 antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 4163US2024190989A1Anti-cea and anti-cd137 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 4262US2024209113A1Anti-gpc3 and anti-cd137 multispecific antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2023·Application pending·0 cites
- 4362US2025170120A1Allosteric sting modulators and methods of useUNIV TEXAS·Filed 2023·Application pending·0 cites
- 4462US2025147019A1Biotin-trap beads and methods of production and use thereofSIEMENS HEALTHCARE DIAGNOSTICS INC·Filed 2022·Application pending·0 cites
- 4560US11673901B2Polycyclic compounds as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jun 13, 2023·0 cites·19 claims
- 4659US2022347241A1Preparation of phage cocktail as therapeutic agent for cow mastitis and use thereofUNIV SHIHEZI·Filed 2022·Application pending·0 cites
- 4759US2021000954A1Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicineSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2020·Application pending·0 cites
- 4858US2024239885A1Antibody conjugate comprising anti-p-cadherin antibody and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 4958US2019167604A1Arylfluorosulfate compounds and methodsSCRIPPS RESEARCH INST·Filed 2019·Application pending·0 cites
- 5057US11779548B2Arylfluorosulfate compounds and methodsSCRIPPS RESEARCH INST·Filed 2020·Granted Oct 10, 2023·0 cites·20 claims
Showing the top 50 of 97 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jie Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →